US drugmakers rise after Trump announces Pfizer price cuts, promises more deals

Pfizer shares rose approximately 5% after the company agreed with the Trump administration to cut prices on Medicaid prescription drugs and offer certain new drugs at a "most favored nation" price, alongside direct-to-consumer sales of specific medications at 40-85% discounts via a new White House website. This deal, the first following presidential pressure for drug price reductions, is viewed by analysts as a potential blueprint for other pharmaceutical companies, suggesting a path for industry pricing concessions that could avert more stringent "most favored nation" policies or tariffs, leading to broader sector gains.

Analysis

Pfizer's agreement with the Trump administration has been positively received by the market, evidenced by a roughly 5% rise in its share price and gains of 3-5% for peers including Merck, Eli Lilly, and AbbVie. This deal, which includes price cuts for Medicaid, direct-to-consumer sales of select drugs like Xeljanz at 40-85% discounts, and adopting a 'most favored nation' price for new drugs, is being interpreted as a significant de-risking event for the pharmaceutical sector. According to BMO Capital Markets, this agreement establishes a viable path for other drugmakers to offer 'headline pricing concessions' without facing more punitive, wide-scale MFN implementation or tariffs, which have been a major overhang. As the first of 17 companies to strike a deal ahead of the September 29 deadline, Pfizer's move provides a potential template that resolves significant regulatory uncertainty, explaining the strongly positive market sentiment despite the price reductions.

Key Decisions for Investors

• The Pfizer deal serves as a potential blueprint for the pharmaceutical industry, reducing the regulatory risk of more severe 'most favored nation' policies and likely providing a positive catalyst for the sector as a whole.
• Investors should view Pfizer's agreement as a net positive, as the market is rewarding the company for gaining regulatory clarity and a first-mover advantage in resolving pricing uncertainty, despite the announced discounts.
• It is crucial to monitor upcoming announcements from other major drugmakers, such as Merck and Eli Lilly, to see if they follow Pfizer's model, as this will confirm the new industry-wide framework for pricing and government relations.